肿瘤坏死因子α拮抗剂在坏疽性脓皮病治疗中的应用进展

Application of tumor necrosis factor-α antagonists in the treatment of pyoderma gangrenosum

坏疽性脓皮病是一种慢性炎症性皮肤病,目前无特效的治疗方法.其发病机制尚不明确,但近期研究表明,坏疽性脓皮病的发生与白细胞介素8、6、1β和肿瘤坏死因子以及干扰素γ等多种细胞因子的上调有关,其中肿瘤坏死因子α是参与坏疽性脓皮病发生和发展的关键细胞因子之一.肿瘤坏死因子α拮抗剂可以靶向阻断肿瘤坏死因子α的生成和活性,近年来已逐渐应用于坏疽性脓皮病的临床治疗中,并取得较好的疗效.目前主要的抗肿瘤坏死因子α拮抗剂有英夫利西、阿达木及依那西普等.

Pyoderma gangrenosum （PG） is a chronic inflammatory dermatosis without specific therapies and definite pathogenesis.Recent researches have indicated that the occurrence of PG is associated with up-regulation of multiple cytokines including intedeukin 8 （IL-8）,IL-6,IL-1β,tumor necrosis factor （TNF） and interferon gamma （IFN-γ）,of which,TNF-o is considered a key cytokine involved in the occurrence and development of PG.TNF-o antagonists can targetly block the production and action of TNF-α,and have been gradually applied to the treatment of PG with a favorable efficacy in clinics.At present,TNF-α antagonists mainly include infliximab,adalimumab and etanercept.